| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| 1688- | SSE, | Potential Role of Selenium in the Treatment of Cancer and Viral Infections |
| - | Review, | Var, | NA |
| 5331- | TFdiG, | Anti-Cancer Properties of Theaflavins |
| - | Review, | Var, | NA |
| 962- | TQ, | Thymoquinone affects hypoxia-inducible factor-1α expression in pancreatic cancer cells via HSP90 and PI3K/AKT/mTOR pathways |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | Nor, | hTERT-HPNE | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | Bxpc-3 |
| 2125- | TQ, | Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | RCC, | Caki-1 |
| 2138- | TQ, | Thymoquinone has a synergistic effect with PHD inhibitors to ameliorate ischemic brain damage in mice |
| - | in-vivo, | Nor, | NA |
| 2139- | TQ, | Thymoquinone regulates microglial M1/M2 polarization after cerebral ischemia-reperfusion injury via the TLR4 signaling pathway |
| - | in-vivo, | Nor, | NA |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 5022- | UA, | Ursolic Acid’s Alluring Journey: One Triterpenoid vs. Cancer Hallmarks |
| - | Review, | Var, | NA |
| 1067- | VitC, | Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer |
| - | in-vivo, | CRC, | NA |
| 596- | VitC, | High-Dose Vitamin C in Advanced-Stage Cancer Patients |
| - | Review, | NA, | NA |
| 632- | VitC, | High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients |
| - | Review, | NA, | NA |
| 3146- | VitC, | Vitamin C protects against hypoxia, inflammation, and ER stress in primary human preadipocytes and adipocytes |
| - | in-vivo, | Nor, | NA |
| 3107- | VitC, | Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment |
| - | Review, | Var, | NA |
| 3114- | VitC, | Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression |
| - | in-vitro, | AML, | NA |
| 3115- | VitC, | The NF-κB Transcriptional Network Is a High-Dose Vitamin C-Targetable Vulnerability in Breast Cancer |
| - | in-vitro, | BC, | NA |
| 1219- | VitC, | Ascorbic acid and ascorbate-2-phosphate decrease HIF activity and malignant properties of human melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 1214- | VitK2, | Vitamin K2 promotes PI3K/AKT/HIF-1α-mediated glycolysis that leads to AMPK-dependent autophagic cell death in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | J82 |
| 1211- | VitK2, | Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells |
| - | in-vitro, | HCC, | HUH7 |
| 2283- | VitK2, | Vitamin K Contribution to DNA Damage—Advantage or Disadvantage? A Human Health Response |
| - | Review, | Var, | NA |
| 2281- | VitK2, | The biological responses of vitamin K2: A comprehensive review |
| - | Review, | Var, | NA |
| 7905- | VT, | Vitexin induces apoptosis and enhances daunorubicin efficacy in acute leukemia via modulation of the HIF-1α/Bcl-2/caspase-3 pathway |
| - | in-vitro, | AML, | APL NB4 |
| 7909- | VT, | Vitexin Inhibits Gastric Cancer Growth and Metastasis through HMGB1-mediated Inactivation of the PI3K/AKT/mTOR/HIF-1α Signaling Pathway |
| - | vitro+vivo, | GC, | NA |
| 7887- | VT, | IVT, | Dietary Flavonoids Vitexin and Isovitexin: New Insights into Their Functional Roles in Human Health and Disease Prevention |
| - | Review, | AD, | NA | - | Review, | Var, | NA |
| 2301- | Wog, | Flavonoids Targeting HIF-1: Implications on Cancer Metabolism |
| - | Review, | Var, | NA |
| 2621- | Wog, | Natural compounds targeting glycolysis as promising therapeutics for gastric cancer: A review |
| - | Review, | Var, | NA |
| 961- | Z, | Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo |
| - | in-vitro, | RCC, | RCC4 | - | vitro+vivo, | GBM, | U373MG | - | in-vitro, | Nor, | HUVECs |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:143 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid